<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36008956</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Association between Galectin Levels and Neurodegenerative Diseases: Systematic Review and Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1062</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom12081062</ELocationID><Abstract><AbstractText>Galectins are a family of proteins with an affinity for &#x3b2;-galactosides that have roles in neuroprotection and neuroinflammation. Several studies indicate that patients with neurodegenerative diseases have alterations in the concentration of galectins in their blood and brain. However, the results of the studies are contradictory; hence, a meta-analysis is performed to clarify whether patients with neurodegenerative diseases have elevated galectin levels compared to healthy individuals. Related publications are obtained from the databases: PubMed, Central-Conchrane, Web of Science database, OVID-EMBASE, Scope, and EBSCO host until February 2022. A pooled standard mean difference (SMD) with a 95% confidence interval (CI) is calculated by fixed-effect or random-effect model analysis. In total, 17 articles are included in the meta-analysis with a total of 905 patients. Patients with neurodegenerative diseases present a higher level of galectin expression compared to healthy individuals (MDS = 0.70, 95% CI 0.28-1.13, <i>p</i> = 0.001). In the subgroup analysis by galectin type, a higher galectin-3 expression is observed in patients with neurodegenerative diseases. Patients with Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALD), and Parkinson's disease (PD) expressed higher levels of galectin-3. Patients with multiple sclerosis (MS) have higher levels of galectin-9. In conclusion, our meta-analysis shows that patients with neurovegetative diseases have higher galectin levels compared to healthy individuals. Galectin levels are associated with the type of disease, sample, detection technique, and region of origin of the patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramos-Mart&#xed;nez</LastName><ForeName>Edgar</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3985-3628</Identifier><AffiliationInfo><Affiliation>Facultad de Qu&#xed;mica, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Coyoac&#xe1;n 04510, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos-Mart&#xed;nez</LastName><ForeName>Iv&#xe1;n</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-3575-8722</Identifier><AffiliationInfo><Affiliation>Departamento de Medicina y Zootecnia de Cerdos, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Coyoac&#xe1;n 04510, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Betancourt</LastName><ForeName>Iv&#xe1;n</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-8201-9669</Identifier><AffiliationInfo><Affiliation>Departamento de Medicina y Zootecnia de Cerdos, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Coyoac&#xe1;n 04510, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos-Mart&#xed;nez</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Departamento de Cardiolog&#xed;a, Hospital General Regional Lic Ignacio Garcia Tellez IMSS, Cuauht&#xe9;moc 97150, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pe&#xf1;a-Corona</LastName><ForeName>Sheila Irais</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Facultad de Qu&#xed;mica, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Coyoac&#xe1;n 04510, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valencia</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1832-8341</Identifier><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n en Endocrinolog&#xed;a, UMAE Hospital de Especialidades, Instituto Mexicano del Seguro Social, Cuauht&#xe9;moc 06720, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saucedo</LastName><ForeName>Renata</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5167-6156</Identifier><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n en Endocrinolog&#xed;a, UMAE Hospital de Especialidades, Instituto Mexicano del Seguro Social, Cuauht&#xe9;moc 06720, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida-Aguirre</LastName><ForeName>Ericka Karol Pamela</ForeName><Initials>EKP</Initials><AffiliationInfo><Affiliation>Facultad de Qu&#xed;mica, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Coyoac&#xe1;n 04510, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerb&#xf3;n</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n en Reproducci&#xf3;n Humana, Instituto Nacional de Perinatolog&#xed;a "Isidro Espinosa de los Reyes"-Facultad de Qu&#xed;mica, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City 04510, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D037502">Galectin 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D037161">Galectins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037502" MajorTopicYN="N">Galectin 3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037161" MajorTopicYN="N">Galectins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">galectin</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword><Keyword MajorTopicYN="N">neurodegenerative diseases</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36008956</ArticleId><ArticleId IdType="pmc">PMC9406080</ArticleId><ArticleId IdType="doi">10.3390/biom12081062</ArticleId><ArticleId IdType="pii">biom12081062</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xu M.-M., Zhou M.-T., Li S.-W., Zhen X.-C., Yang S. Glycoproteins as Diagnostic and Prognostic Biomarkers for Neurodegenerative Diseases: A Glycoproteomic Approach. J. Neurosci. Res. 2021;99:1308&#x2013;1324. doi: 10.1002/jnr.24805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.24805</ArticleId><ArticleId IdType="pubmed">33634546</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P.-P., Xie Y., Meng X.-Y., Kang J.-S. History and Progress of Hypotheses and Clinical Trials for Alzheimer&#x2019;s Disease. Signal Transduct. Target. Ther. 2019;4:29. doi: 10.1038/s41392-019-0063-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-019-0063-8</ArticleId><ArticleId IdType="pmc">PMC6799833</ArticleId><ArticleId IdType="pubmed">31637009</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacour D., Koch A., Jacob R. The Role of Galectins in Protein Trafficking. Traffic. 2009;10:1405&#x2013;1413. doi: 10.1111/j.1600-0854.2009.00960.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0854.2009.00960.x</ArticleId><ArticleId IdType="pubmed">19650851</ArticleId></ArticleIdList></Reference><Reference><Citation>Funasaka T., Raz A., Nangia-Makker P. Nuclear Transport of Galectin-3 and Its Therapeutic Implications. Semin. Cancer Biol. 2014;27:30&#x2013;38. doi: 10.1016/j.semcancer.2014.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2014.03.004</ArticleId><ArticleId IdType="pmc">PMC4108496</ArticleId><ArticleId IdType="pubmed">24657939</ArticleId></ArticleIdList></Reference><Reference><Citation>Nio-Kobayashi J. Tissue- and Cell-Specific Localization of Galectins, &#x3b2;-Galactose-Binding Animal Lectins, and Their Potential Functions in Health and Disease. Anat. Sci. Int. 2017;92:25&#x2013;36. doi: 10.1007/s12565-016-0366-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12565-016-0366-6</ArticleId><ArticleId IdType="pubmed">27590897</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Mart&#xed;nez J.C., Altamirano-G&#xf3;mez G., Ramos-Mart&#xed;nez I., Valencia J., Hern&#xe1;ndez-Zimbr&#xf3;n L., Hern&#xe1;ndez-Ju&#xe1;rez J., Echeverr&#xed;a-V&#xe1;squez P., Hern&#xe1;ndez-Gonz&#xe1;lez L.L., P&#xe9;rez-Campos E., P&#xe9;rez-Campos Mayoral L., et al. Prognostic Value of Galectin Expression in Patients with Breast Cancer: Systematic Review and Meta-Analysis. Clin. Breast Cancer. 2021 doi: 10.1016/j.clbc.2021.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clbc.2021.12.011</ArticleId><ArticleId IdType="pubmed">35058144</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkerke H., Dias-Baruffi M., Cummings R.D., Arthur C.M., Stowell S.R. Galectins. Volume 2442. Humana Press; New York, NY, USA: 2022. Galectins: An Ancient Family of Carbohydrate Binding Proteins with Modern Functions; pp. 1&#x2013;40. (Methods in Molecular Biology).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-2055-7_1</ArticleId><ArticleId IdType="pubmed">35320517</ArticleId></ArticleIdList></Reference><Reference><Citation>Cengiz T., Turkboylari S., Gencler O.S., Anlar O. The Roles of Galectin-3 and Galectin-4 in the Idiopatic Parkinson Disease and Its Progression. Clin. Neurol. Neurosurg. 2019;184:105373. doi: 10.1016/j.clineuro.2019.105373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2019.105373</ArticleId><ArticleId IdType="pubmed">31147178</ArticleId></ArticleIdList></Reference><Reference><Citation>Stancic M., van Horssen J., Thijssen V.L., Gabius H.-J., van der Valk P., Hoekstra D., Baron W. Increased Expression of Distinct Galectins in Multiple Sclerosis Lesions. Neuropathol. Appl. Neurobiol. 2011;37:654&#x2013;671. doi: 10.1111/j.1365-2990.2011.01184.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2011.01184.x</ArticleId><ArticleId IdType="pubmed">21501208</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubiri I., Lombardi V., Bremang M., Mitra V., Nardo G., Adiutori R., Lu C.-H., Leoni E., Yip P., Yildiz O., et al. Tissue-Enhanced Plasma Proteomic Analysis for Disease Stratification in Amyotrophic Lateral Sclerosis. Mol. Neurodegener. 2018;13:60. doi: 10.1186/s13024-018-0292-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0292-2</ArticleId><ArticleId IdType="pmc">PMC6223075</ArticleId><ArticleId IdType="pubmed">30404656</ArticleId></ArticleIdList></Reference><Reference><Citation>Boza-Serrano A., Ruiz R., Sanchez-Varo R., Garcia-Revilla J., Yang Y., Jimenez-Ferrer I., Paulus A., Wennstroem M., Vilalta A., Allendorf D., et al. Galectin-3, a Novel Endogenous TREM2 Ligand, Detrimentally Regulates Inflammatory Response in Alzheimer&#x2019;s Disease. ACTA Neuropathol. 2019;138:251&#x2013;273. doi: 10.1007/s00401-019-02013-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02013-z</ArticleId><ArticleId IdType="pmc">PMC6660511</ArticleId><ArticleId IdType="pubmed">31006066</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara A., Niwa M., Noguchi K., Kanayama T., Niwa A., Matsuo M., Hatano Y., Tomita H. Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases. Biomolecules. 2020;10:389. doi: 10.3390/biom10030389.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10030389</ArticleId><ArticleId IdType="pmc">PMC7175224</ArticleId><ArticleId IdType="pubmed">32138174</ArticleId></ArticleIdList></Reference><Reference><Citation>Puigdell&#xed;vol M., Allendorf D.H., Brown G.C. Sialylation and Galectin-3 in Microglia-Mediated Neuroinflammation and Neurodegeneration. Front. Cell. Neurosci. 2020;14:162. doi: 10.3389/fncel.2020.00162.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.00162</ArticleId><ArticleId IdType="pmc">PMC7296093</ArticleId><ArticleId IdType="pubmed">32581723</ArticleId></ArticleIdList></Reference><Reference><Citation>Siew J.J., Chen H.-M., Chen H.-Y., Chen H.-L., Chen C.-M., Soong B.-W., Wu Y.-R., Chang C.-P., Chan Y.-C., Lin C.-H., et al. Galectin-3 Is Required for the Microglia-Mediated Brain Inflammation in a Model of Huntington&#x2019;s Disease. Nat. Commun. 2019;10:3473. doi: 10.1038/s41467-019-11441-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11441-0</ArticleId><ArticleId IdType="pmc">PMC6677843</ArticleId><ArticleId IdType="pubmed">31375685</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2535</ArticleId><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Hozo S.P., Djulbegovic B., Hozo I. Estimating the Mean and Variance from the Median, Range, and the Size of a Sample. BMC Med. Res. Methodol. 2005;5:13. doi: 10.1186/1471-2288-5-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-5-13</ArticleId><ArticleId IdType="pmc">PMC1097734</ArticleId><ArticleId IdType="pubmed">15840177</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohatgi A. Web Plot Digitizer (Version No. 4.5). Windows. California. 2021.  [(accessed on 13 June 2022)].  Available online:  https://automeris.io/WebPlotDigitizer.</Citation></Reference><Reference><Citation>DerSimonian R., Laird N. Meta-Analysis in Clinical Trials. Control. Clin. Trials. 1986;7:177&#x2013;188. doi: 10.1016/0197-2456(86)90046-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantel N., Haenszel W. Statistical Aspects of the Analysis of Data from Retrospective Studies of Disease. J. Natl. Cancer Inst. 1959;22:719&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">13655060</ArticleId></ArticleIdList></Reference><Reference><Citation>Duval S., Tweedie R. A Nonparametric &#x201c;Trim and Fill&#x201d; Method of Accounting for Publication Bias in Meta-Analysis. J. Am. Stat. Assoc. 2000;95:89&#x2013;98. doi: 10.1080/01621459.2000.10473905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.2000.10473905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato T., Kurita K., Seino T., Kadoya T., Horie H., Wada M., Kawanami T., Daimon M., Hirano A. Galectin-1 Is a Component of Neurofilamentous Lesions in Sporadic and Familial Amyotrophic Lateral Sclerosis. Biochem. Biophys. Res. Commun. 2001;282:166&#x2013;172. doi: 10.1006/bbrc.2001.4556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.2001.4556</ArticleId><ArticleId IdType="pubmed">11263987</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jong C.G.H.M., Stancic M., Pinxterhuis T.H., van Horssen J., van Dam A.-M., Gabius H.-J., Baron W. Galectin-4, a Negative Regulator of Oligodendrocyte Differentiation, Is Persistently Present in Axons and Microglia/Macrophages in Multiple Sclerosis Lesions. J. Neuropathol. Exp. Neurol. 2018;77:1024&#x2013;1038. doi: 10.1093/jnen/nly081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nly081</ArticleId><ArticleId IdType="pubmed">30252090</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y.-J., Shi Q., Yang X.-D., Li J.-L., Ma Y., Xiao K., Chen C., Han J., Dong X.-P. Increases of Galectin-1 and Its S-Nitrosylated Form in the Brain Tissues of Scrapie-Infected Rodent Models and Human Prion Diseases. Mol. Neurobiol. 2017;54:3707&#x2013;3716. doi: 10.1007/s12035-016-9923-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-9923-1</ArticleId><ArticleId IdType="pubmed">27211330</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazar T., Olgun Yazar H., Cihan M. Evaluation of Serum Galectin-3 Levels at Alzheimer Patients by Stages: A Preliminary Report. Acta Neurol. Belg. 2021;121:949&#x2013;954. doi: 10.1007/s13760-020-01477-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13760-020-01477-1</ArticleId><ArticleId IdType="pubmed">32852752</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques T.M., van Rumund A., Bruinsma I.B., Wessels H.J.C.T., Gloerich J., Esselink R.A.J., Bloem B.R., Kuiperij H.B., Verbeek M.M. Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls. Mol. Neurobiol. 2019;56:5067&#x2013;5074. doi: 10.1007/s12035-018-1426-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1426-9</ArticleId><ArticleId IdType="pmc">PMC6647396</ArticleId><ArticleId IdType="pubmed">30465235</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Niu Y., Yue C.-X., Fu S., Wang R.-T. Increased Ileal Bile Acid Binding Protein and Galectin-9 Are Associated with Mild Cognitive Impairment and Alzheimer&#x2019;s Disease. J. Psychiatr. Res. 2019;119:102&#x2013;106. doi: 10.1016/j.jpsychires.2019.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2019.10.002</ArticleId><ArticleId IdType="pubmed">31593867</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan J., Xu Y., Zhang L., Zhao H., Jin L., Liu W.-G., Weng L.-H., Li Z.-H., Chen L. Increased Expressions of Plasma Galectin-3 in Patients with Amyotrophic Lateral Sclerosis. Chin. Med. J. 2016;129:2797&#x2013;2803. doi: 10.4103/0366-6999.194656.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0366-6999.194656</ArticleId><ArticleId IdType="pmc">PMC5146785</ArticleId><ArticleId IdType="pubmed">27900991</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J.-Y., Afjehi-Sadat L., Asress S., Duong D.M., Cudkowicz M., Glass J.D., Peng J. Galectin-3 Is a Candidate Biomarker for Amyotrophic Lateral Sclerosis: Discovery by a Proteomics Approach. J. Proteome Res. 2010;9:5133&#x2013;5141. doi: 10.1021/pr100409r.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr100409r</ArticleId><ArticleId IdType="pmc">PMC2948604</ArticleId><ArticleId IdType="pubmed">20698585</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Zhang S., Lin F., Chu W., Yue S. Elevated Galectin-3 Levels in the Serum of Patients With Alzheimer&#x2019;s Disease. Am. J. Alzheimers Dis. Other Dement. 2015;30:729&#x2013;732. doi: 10.1177/1533317513495107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1533317513495107</ArticleId><ArticleId IdType="pubmed">23823143</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashraf G.M., Baeesa S.S. Investigation of Gal-3 Expression Pattern in Serum and Cerebrospinal Fluid of Patients Suffering From Neurodegenerative Disorders. Front. Neurosci. 2018;12:430. doi: 10.3389/fnins.2018.00430.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00430</ArticleId><ArticleId IdType="pmc">PMC6033997</ArticleId><ArticleId IdType="pubmed">30008660</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian P.-C., Wang H.-L., Chen G.-H., Li J.-H., Zheng C., Wang Y., Tian P.-C., Wang H.-L., Chen G.-H., Li J.-H., et al. Elevated Interictal Serum Galectin-3 Levels in Intractable Epilepsy. Neurol. India. 2016;64:233&#x2013;236. doi: 10.4103/0028-3886.177618.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0028-3886.177618</ArticleId><ArticleId IdType="pubmed">26954798</ArticleId></ArticleIdList></Reference><Reference><Citation>Burman J., Svenningsson A. Cerebrospinal Fluid Concentration of Galectin-9 Is Increased in Secondary Progressive Multiple Sclerosis. J. Neuroimmunol. 2016;292:40&#x2013;44. doi: 10.1016/j.jneuroim.2016.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2016.01.008</ArticleId><ArticleId IdType="pubmed">26943957</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso M., Giraudo S., Corpillo D., Bergamasco B., Lopiano L., Fasano M. Proteome Analysis of Human Substantia Nigra in Parkinson&#x2019;s Disease. Proteomics. 2004;4:3943&#x2013;3952. doi: 10.1002/pmic.200400848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.200400848</ArticleId><ArticleId IdType="pubmed">15526345</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner C.J., Haussen R.H., Mall G., Wolf S. Proteome Analysis of Human Substantia Nigra in Parkinson&#x2019;s Disease. Proteome Sci. 2008;6:8. doi: 10.1186/1477-5956-6-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-5956-6-8</ArticleId><ArticleId IdType="pmc">PMC2265686</ArticleId><ArticleId IdType="pubmed">18275612</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao C.-C., Cheng K.-M., Ma Y.-L., Hsu W.-L., Chen Y.-C., Fuh J.-L., Lee W.-J., Chao C.-C., Lee E.H.Y. Galectin-3 Promotes A Beta Oligomerization and A Beta Toxicity in a Mouse Model of Alzheimer&#x2019;s Disease. Cell Death Differ. 2020;27:192&#x2013;209. doi: 10.1038/s41418-019-0348-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-019-0348-z</ArticleId><ArticleId IdType="pmc">PMC7206130</ArticleId><ArticleId IdType="pubmed">31127200</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H.-C., Chang K.-H., Chiang M.-C., Chen C.-M. Alterations of Plasma Galectin-3 and C3 Levels in Patients with Parkinson&#x2019;s Disease. Brain Sci. 2021;11:1515. doi: 10.3390/brainsci11111515.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11111515</ArticleId><ArticleId IdType="pmc">PMC8615685</ArticleId><ArticleId IdType="pubmed">34827514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wada M., Ono S., Kadoya T., Kawanami T., Kurita K., Kato T. Decreased Galectin-1 Immunoreactivity of the Skin in Amyotrophic Lateral Sclerosis. J. Neurol. Sci. 2003;208:67&#x2013;70. doi: 10.1016/S0022-510X(02)00424-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(02)00424-0</ArticleId><ArticleId IdType="pubmed">12639727</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P.T., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., Welch V.A. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley &amp; Sons; Chichester, UK: 2019. Collecting Data.</Citation><ArticleIdList><ArticleId IdType="pubmed">31643080</ArticleId></ArticleIdList></Reference><Reference><Citation>Burguillos M.A., Svensson M., Schulte T., Boza-Serrano A., Garcia-Quintanilla A., Kavanagh E., Santiago M., Viceconte N., Oliva-Martin M.J., Osman A.M., et al. Microglia-Secreted Galectin-3 Acts as a Toll-like Receptor 4 Ligand and Contributes to Microglial Activation. Cell Rep. 2015;10:1626&#x2013;1638. doi: 10.1016/j.celrep.2015.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.02.012</ArticleId><ArticleId IdType="pubmed">25753426</ArticleId></ArticleIdList></Reference><Reference><Citation>Itabashi T., Arima Y., Kamimura D., Higuchi K., Bando Y., Takahashi-Iwanaga H., Murakami M., Watanabe M., Iwanaga T., Nio-Kobayashi J. Cell- and Stage-Specific Localization of Galectin-3, a &#x3b2;-Galactoside-Binding Lectin, in a Mouse Model of Experimental Autoimmune Encephalomyelitis. Neurochem. Int. 2018;118:176&#x2013;184. doi: 10.1016/j.neuint.2018.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2018.06.007</ArticleId><ArticleId IdType="pubmed">29920290</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajitani K., Nomaru H., Ifuku M., Yutsudo N., Dan Y., Miura T., Tsuchimoto D., Sakumi K., Kadoya T., Horie H., et al. Galectin-1 Promotes Basal and Kainate-Induced Proliferation of Neural Progenitors in the Dentate Gyrus of Adult Mouse Hippocampus. Cell Death Differ. 2009;16:417&#x2013;427. doi: 10.1038/cdd.2008.162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2008.162</ArticleId><ArticleId IdType="pubmed">19008923</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai X.Y., Bernhardt B., Thom M., Thompson P., Baxendale S., Koepp M., Bernasconi N. Review: Neurodegenerative Processes in Temporal Lobe Epilepsy with Hippocampal Sclerosis: Clinical, Pathological and Neuroimaging Evidence. Neuropathol. Appl. Neurobiol. 2018;44:70&#x2013;90. doi: 10.1111/nan.12458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12458</ArticleId><ArticleId IdType="pubmed">29288503</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolinski P., Ksiazek-Winiarek D., Glabinski A. Cytokines and Neurodegeneration in Epileptogenesis. Brain Sci. 2022;12:380. doi: 10.3390/brainsci12030380.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci12030380</ArticleId><ArticleId IdType="pmc">PMC8945903</ArticleId><ArticleId IdType="pubmed">35326336</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez Hern&#xe1;ndez E., S&#xe1;nchez-Maldonado C., Mayoral Ch&#xe1;vez M.A., Hern&#xe1;ndez-Zimbr&#xf3;n L.F., Patricio Mart&#xed;nez A., Zenteno E., Lim&#xf3;n P&#xe9;rez de Le&#xf3;n I.D. The therapeutic potential of galectin-1 and galectin-3 in the treatment of neurodegenerative diseases. Expert Rev. Neurother. 2022;20:439&#x2013;448. doi: 10.1080/14737175.2020.1750955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2020.1750955</ArticleId><ArticleId IdType="pubmed">32303136</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon S.B., Yoon H.J., Chang C.Y., Koh H.S., Jeon S.H., Park E.J. Galectin-3 exerts cytokine-like regulatory actions through the JAK-STAT pathway. J. Immunol. 2010;185:7037&#x2013;7046. doi: 10.4049/jimmunol.1000154.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1000154</ArticleId><ArticleId IdType="pubmed">20980634</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyos H.C., Marder M., Ulrich R., Gudi V., Stangel M., Rabinovich G.A., Pasquini L.A., Pasquini J.M. The Role of Galectin-3: From Oligodendroglial Differentiation and Myelination to Demyelination and Remyelination Processes in a Cuprizone-Induced Demyelination Model. Adv. Exp. Med. Biol. 2016;949:311&#x2013;332. doi: 10.1007/978-3-319-40764-7_15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-40764-7_15</ArticleId><ArticleId IdType="pubmed">27714696</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H.-R., Al Rasebi Z., Mensah-Brown E., Shahin A., Xu D., Goodyear C.S., Fukada S.Y., Liu F.-T., Liew F.Y., Lukic M.L. Galectin-3 Deficiency Reduces the Severity of Experimental Autoimmune Encephalomyelitis. J. Immunol. 2009;182:1167&#x2013;1173. doi: 10.4049/jimmunol.182.2.1167.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.182.2.1167</ArticleId><ArticleId IdType="pubmed">19124760</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Chen N., Wu C., Lu Y., Gao G., Duan C., Yang H., Lu L. Galectin-1 Attenuates Neurodegeneration in Parkinson&#x2019;s Disease Model by Modulating Microglial MAPK/I&#x3ba;B/NF&#x3ba;B Axis through Its Carbohydrate-Recognition Domain. Brain Behav. Immun. 2020;83:214&#x2013;225. doi: 10.1016/j.bbi.2019.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2019.10.015</ArticleId><ArticleId IdType="pubmed">31669519</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Z., Xu H., Song W., Hu C., Guo M., Li J., Li J. Galectin-1 ameliorates perioperative neurocognitive disorders in aged mice. CNS Neurosci. Ther. 2021;27:842&#x2013;856. doi: 10.1111/cns.13645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.13645</ArticleId><ArticleId IdType="pmc">PMC8193703</ArticleId><ArticleId IdType="pubmed">33942523</ArticleId></ArticleIdList></Reference><Reference><Citation>Starossom S.C., Mascanfroni I.D., Imitola J., Cao L., Raddassi K., Hernandez S.F., Bassil R., Croci D.O., Cerliani J.P., Delacour D., et al. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity. 2012;37:249&#x2013;263. doi: 10.1016/j.immuni.2012.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.05.023</ArticleId><ArticleId IdType="pmc">PMC3428471</ArticleId><ArticleId IdType="pubmed">22884314</ArticleId></ArticleIdList></Reference><Reference><Citation>Quint&#xe1; H.R., Pasquini J.M., Rabinovich G.A., Pasquini L.A. Glycan-dependent binding of galectin-1 to neuropilin-1 promotes axonal regeneration after spinal cord injury. Cell Death Differ. 2014;21:941&#x2013;955. doi: 10.1038/cdd.2014.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2014.14</ArticleId><ArticleId IdType="pmc">PMC4013512</ArticleId><ArticleId IdType="pubmed">24561343</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu W.S., Wang Y.H., Wang J.P., Tang Y.X., Zhang Q., Tian D.S., Yu Z.Y., Xie M.J., Wang W. Galectin-1 enhances astrocytic BDNF production and improves functional outcome in rats following ischemia. Neurochem. Res. 2010;35:1716&#x2013;1724. doi: 10.1007/s11064-010-0234-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-010-0234-z</ArticleId><ArticleId IdType="pubmed">20689988</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B., Noad J., McMahon H., Randow F., Goedert M. Galectin-8-Mediated Selective Autophagy Protects against Seeded Tau Aggregation. J. Biol. Chem. 2018;293:2438&#x2013;2451. doi: 10.1074/jbc.M117.809293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M117.809293</ArticleId><ArticleId IdType="pmc">PMC5818177</ArticleId><ArticleId IdType="pubmed">29282296</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardo E., Barake F., Godoy J.A., Oyanadel C., Espinoza S., Metz C., Retamal C., Massardo L., Tapia-Rojas C., Inestrosa N.C., et al. GALECTIN-8 Is a Neuroprotective Factor in the Brain That Can Be Neutralized by Human Autoantibodies. Mol. Neurobiol. 2019;56:7774&#x2013;7788. doi: 10.1007/s12035-019-1621-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1621-3</ArticleId><ArticleId IdType="pubmed">31119556</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardo E., C&#xe1;rcamo C., Uribe-San Mart&#xed;n R., Ciampi E., Segovia-Miranda F., Curkovic-Pe&#xf1;a C., Montecino F., Holmes C., Tichauer J.E., Acu&#xf1;a E., et al. Galectin-8 as an Immunosuppressor in Experimental Autoimmune Encephalomyelitis and a Target of Human Early Prognostic Antibodies in Multiple Sclerosis. PLoS ONE. 2017;12:e0177472. doi: 10.1371/journal.pone.0177472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0177472</ArticleId><ArticleId IdType="pmc">PMC5484466</ArticleId><ArticleId IdType="pubmed">28650992</ArticleId></ArticleIdList></Reference><Reference><Citation>Nio-Kobayashi J., Itabashi T. Galectins and Their Ligand Glycoconjugates in the Central Nervous System Under Physiological and Pathological Conditions. Front. Neuroanat. 2021;15:767330. doi: 10.3389/fnana.2021.767330.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2021.767330</ArticleId><ArticleId IdType="pmc">PMC8554236</ArticleId><ArticleId IdType="pubmed">34720894</ArticleId></ArticleIdList></Reference><Reference><Citation>Steelman A.J., Smith R., 3rd, Welsh C.J., Li J. Galectin-9 protein is up-regulated in astrocytes by tumor necrosis factor and promotes encephalitogenic T-cell apoptosis. J. Biol. Chem. 2013;288:23776&#x2013;23787. doi: 10.1074/jbc.M113.451658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.451658</ArticleId><ArticleId IdType="pmc">PMC3745324</ArticleId><ArticleId IdType="pubmed">23836896</ArticleId></ArticleIdList></Reference><Reference><Citation>Steelman A.J., Li J. Astrocyte galectin-9 potentiates microglial TNF secretion. J. Neuroinflamm. 2014;11:144. doi: 10.1186/s12974-014-0144-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-014-0144-0</ArticleId><ArticleId IdType="pmc">PMC4158089</ArticleId><ArticleId IdType="pubmed">25158758</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang T., Ma C., Wang T., Deng R., Ding J., Wang W., Xu Z., Li X., Li H., Sun Q., et al. Galectin-9 Promotes Neuronal Restoration via Binding TLR-4 in a Rat Intracerebral Hemorrhage Model. Neuromol. Med. 2021;23:267&#x2013;284. doi: 10.1007/s12017-020-08611-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-020-08611-5</ArticleId><ArticleId IdType="pubmed">32865657</ArticleId></ArticleIdList></Reference><Reference><Citation>Cioca A., Muntean D., Bungardean C., Raica M., Cimpean A.M. Expression and Distribution of Galectin-3 in Chromophobe and Papillary Carcinomas. Anticancer Res. 2018;38:259&#x2013;263. doi: 10.21873/anticanres.12216.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/anticanres.12216</ArticleId><ArticleId IdType="pubmed">29277781</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Br&#xfb;le F.A., Waltregny D., Liu F.T., Castronovo V. Alteration of the Cytoplasmic/Nuclear Expression Pattern of Galectin-3 Correlates with Prostate Carcinoma Progression. Int. J. Cancer. 2000;89:361&#x2013;367. doi: 10.1002/1097-0215(20000720)89:4&lt;361::AID-IJC8&gt;3.0.CO;2-U.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0215(20000720)89:4&lt;361::AID-IJC8&gt;3.0.CO;2-U</ArticleId><ArticleId IdType="pubmed">10956411</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>